Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 8/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10359587 | 0.81 | TBXAS1 (0.36) | CYP24A1TBXAS1ALDH1A1GPR119 | |
| SCHEMBL29247460 | 0.80 | CYP24A1 (0.35) | CYP24A1TBXAS1ALDH1A1GPR119 | |
| SCHEMBL13479037 | 0.79 | TBXAS1 (0.35) | CYP24A1TBXAS1ALDH1A1GPR119 | |
| SCHEMBL217823 | 0.77 | GPR119 (0.42) | CYP24A1TBXAS1L3MBTL1GPR119 | |
| SCHEMBL17026721 | 0.77 | TBXAS1 (0.37) | CYP24A1TBXAS1 | |
| SCHEMBL12093553 | 0.76 | CYP24A1 (0.36) | CYP24A1TBXAS1ALDH1A1GPR119 | |
| SCHEMBL23604883 | 0.76 | AHR (0.31) | CYP24A1TBXAS1 | |
| SCHEMBL1199386 | 0.75 | AHR (0.36) | CYP24A1TBXAS1ALDH1A1GPR119 | |
| SCHEMBL26492704 | 0.75 | TBXAS1 (0.32) | CYP24A1TBXAS1 | |
| SCHEMBL16391056 | 0.74 | CYP24A1 (0.32) | CYP24A1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144914-B2 | 3,7-diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2006-12-05 | — | — | US | disclosed |
| EP-1360187-B1 | 3,7-DIAZABICYCLO(3.3.0)OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| US-20040053986-A1 | 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2004-03-18 | — | — | US | disclosed |
| US-6559162-B2 | Electrophysiological activity | ASTRAZENECA AB (SE) | 2003-05-06 | — | — | US | disclosed |
| US-20020137766-A1 | Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053986-A1 | 3,7-Diazabicyclo[3.3.0]octanes and their use in the treatment of cardiac arrhythmias | KCNH1, KCNH2, CACNA1E | CYP24A1 285/4885TBXAS1 769/4885L3MBTL1 936/4885 |
| US-20020137766-A1 | Azabicyclooctane derivatives useful in the treatment of cardiac arrhythmias | KCNH1, KCNH2, KCNH3 | CYP24A1 243/4885TBXAS1 641/4885L3MBTL1 2420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.